Keros Therapeutics (KROS) Free Cash Flow (2019 - 2025)

Keros Therapeutics has reported Free Cash Flow for 7 years, with the latest figure at -$25.9 million in Q4 2025.

• For the quarter ending Q4 2025, Free Cash Flow rose 44.1% year-over-year to -$25.9 million; the trailing twelve-month figure through Dec 2025 stood at $107.5 million (up 166.03% YoY), and the FY2025 full-year result was $107.5 million, up 166.03% from the prior year.
• Free Cash Flow for Q4 2025 stood at -$25.9 million, down from $1.8 million in the prior quarter.
• The five-year high for Free Cash Flow was $160.6 million in Q1 2025, with the low at -$46.3 million in Q4 2024.
• Historically, Free Cash Flow has averaged -$15.7 million across 5 years, with a median of -$25.2 million in 2022.
• Annual changes were most pronounced in 2023 — Free Cash Flow sank 2162.62% — and 2025, when it soared 458.58%.
• Keros Therapeutics' Free Cash Flow stood at -$19.7 million in 2021, then decreased by 14.94% to -$22.7 million in 2022, then dropped by 14.68% to -$26.0 million in 2023, then plunged by 78.08% to -$46.3 million in 2024, then surged by 44.1% to -$25.9 million in 2025.
• The last three Free Cash Flow figures came in at -$25.9 million (Q4 2025), $1.8 million (Q3 2025), and -$29.1 million (Q2 2025), per Business Quant data.